[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the stability and efficacy after administration of
[177Lu]Ludotadipep in patients with metastatic castration resistant prostate cancer (mCRPC),
with dose-escalation applied to determine the appropriate dose.